For US Healthcare Professionals

Sotalol IV Logo

[Podcast] Review of a Sotalol IV Retrospective Study Presented at ACC.24

The Sotalol IV Podcast


Continuing our conversation with Dr. Keturah DelGrosso (née Weaver), we explore a retrospective study presented at ACC.24 comparing the real-world effectiveness and safety of intravenous to oral sotalol loading. 

About Dr. Eva Nelson: 

Eva Nelson, MD, RPh is AltaThera Pharmaceuticals’ Director of Education and Training. She has decades of experience as a physician, anesthesiologist, healthcare advocate, and educator.

About Dr. Keturah DelGrosso

Dr. DelGrosso currently serves as the Director of Geisinger’s PGY1 Pharmacy Residency Program, as well as being a clinical pharmacist in cardiology in Geisinger’s Medication Therapy Disease Management program.

Dr. DelGrosso is a graduate of Lake Erie College of Osteopathic Medicine School of Pharmacy. She completed her pre-pharmacy studies at the University of Pittsburgh and went on to earn her Doctor of Pharmacy degree in 2018. After graduation, she completed a PGY1 pharmacy practice residency at Conemaugh Memorial Medical Center in Johnstown, Pennsylvania.

Her professional interests include preventive medicine, diabetes, hypertension, heart failure, dyslipidemia, smoking cessation, teaching and transitions of care.


  1. Sotalol IV [package insert]. Chicago, IL: AltaThera Pharmaceuticals; 2023.
  2. BetaPace [package insert]. Zug, Switzerland: Covis Pharma; 2023.
  3. Somberg JC, Vinks AA, Dong M, Molnar J. Model-Informed Development of Sotalol Loading and Dose Escalation
    Employing an Intravenous Infusion. Cardiol Res. 2020;11(5):294-304. doi:10.14740/cr1143
  4. Weaver, K, Heikkinen, B, Novak, M. REAL-WORLD COMPARATIVE EFFECTIVENESS AND SAFETY OF INTRAVENOUS TO ORAL SOTALOL LOADING AMONG PATIENTS WITH ATRIAL ARRHYTHMIAS. J Am Coll Cardiol. 2024 Apr, 83 (13_Supplement) 8. doi:10.1016/S0735-1097(24)01998-3

Highlights of Prescribing Information

Boxed Warning, Indications, and Important Safety Information


Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation. To minimize the risk of drug induced arrhythmia, initiate or uptitrate intravenous sotalol in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)].
Do not initiate intravenous sotalol therapy if the baseline QTc is longer than 450 ms. If the QTc prolongs to 500 ms or greater, reduce the dose or discontinue. (2.3)